Median Technologies Receives the Forbes 2018 Futur40 Award and Special Recognition Prize for the Health-Life Sciences Company Category

Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®,
announces that on July 11, it received the 2018 Futur40 award and
special recognition prize in the category “Health-Life Sciences”. These
prizes are awarded by Forbes, PMEFinance-EuropeEntrepreneurs
and their partners Euronext, MorningStar, RSM, F2iC and Paris Europlace
to distinguish French champions of growth.

“We are very proud to receive the Futur40 award and this special
recognition in Health and Life Sciences”, said Fredrik Brag, CEO of
Median Technologies. “These awards highlight the importance of SMEs
and MidCaps in the Paris international financial center. Median received
the Futur40 award in 2017 and it’s an honor to be back in the charts for
this year”, he added.

The Futur40 ranking is based on data provided by Morningstar and
highlights the 40 Paris-listed companies that have distinguished
themselves based on their financial performance and the originality of
their business model. The criteria for winning the Futur40 award are as

The special recognition prize highlights seven companies with exemplary
track records, each of these companies belonging to a different category.

About Median Technologies: Median Technologies provides
innovative imaging solutions and services to advance healthcare for
everyone. We leverage the power of Imaging Phenomics to provide insights
into novel therapies and treatment strategies. Our unique solutions,
MediScan® for Patient Care, iSee® and ImageBank™ for image management in
clinical trials and iBiopsy® for imaging phenotyping, together with our
global team of experts, are advancing the development of new drugs and
diagnostic tools to monitor disease and assess response to therapy.
Median Technologies supports biopharmaceutical sponsors and healthcare
professionals around the world to quickly and precisely bring new
treatments to patients in need, with an eye on reducing overall care
costs. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary
in Boston, Median has received the label “Innovative company” by the BPI
and is listed on Euronext Growth market (ISIN: FR0011049824, ticker:
ALMDT). The company is eligible for the PEA-PME SME equity savings plan
setup and has received the label Pass French Tech Promotion 2017-2018.
Median Technologies has been awarded the 2018 Tech 40 Label, and is a
winner of the Deloitte Technology Fast 500™ 2017 EMEA program. Median is
a member of the Bpifrance Excellence Network. For more information:

View source version on

Leave a Comment